Nuclear Medicine

Nuclear Medicine > Radionuclide Therapy

Radionuclide Therapy


Xofigo is the therapeutic alpha particle-emitting pharmaceutical that is indicated for the treatment of castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease.


Xofigo® mimics calcium and selectively targets bone,  specifically areas of bone metatases, by forming complexes with the bone mineral hydroxyapatite.


The short range of alpha particles emmited by Xofigo (<10 cell diameters) gives them a highly localized radius of action, minimizing damage to surrounding normal tissues.


Xofigo emits alpha partices that lead to high frequency of double-strand DNA breaks in adjacent tumor cells resulting in a potent cytotoxic effect on bone metatases.

Benefits of Xofigo:

  • 30% reduction on the risk of death.
    — 6 month increase in median overall survival (14.9 months vs 11.3 months)
  • 34% reduction on the risk of symptomatic skeletal events (SSEs).
    — Median time to first SSE was significantly delayed by 5.8 months vs placebo
  • The number of patients who had adverse events after they received the study drug was consistently lower in the Xofigo group than in the placebo group for all adverse events.
  • Patients may return home immediately following injection, with no restrictions regarding contact with other people.


  1. Xofigo® (radium Ra 223 dichloride) injection [prescribing information]. Singapore, July 2015.
  2. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-223.
  3. Mohler JL, Armstrong AJ, Bahnson RR, et al; for the NCCN Guidelines Panel Members. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer. Version 1 .201 5. National Comprehensive Cancer Network®; 2015.

Thank you for getting in touch with us, we will follow up with your enquiry by 2 working days.